Your First Choice Journal in Men's Health
Open Access, Peer-reviewed
Indexed in SCIE, SCOPUS, DOAJ and More
pISSN 2287-4208  eISSN 2287-4690
    World J Mens Health. 2021 Apr;39(2):208-221. English.
    Published online Mar 09, 2020.
    https://doi.org/10.5534/wjmh.200010
    Copyright © 2021 Korean Society for Sexual Medicine and Andrology
    Review

    Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review

    Young Jin Tak,1,2 and Sang Yeoup Lee3,4
      • 1Department of Family Medicine, Pusan National University School of Medicine, Yangsan, Korea.
      • 2Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
      • 3Family Medicine Clinic and Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.
      • 4Department of Medical Education, Pusan National University School of Medicine, Yangsan, Korea.
    • Correspondence to: Sang Yeoup Lee. Family Medicine Clinic, Pusan National University Yangsan Hospital, 20 Geumo-ro, Mulgeum-eup, Yangsan 50612, Korea. Tel: +82-55-360-1442, Fax: +82-51-510-8125, Email: saylee@pnu.edu
    Received January 13, 2020; Revised February 05, 2020; Accepted February 16, 2020.

    This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Abstract

    As a chronic and relapsing disease, obesity negatively impacts the health of men to a greater extent than that of women, with a higher risk of cardiovascular disease. Since lifestyle modifications alone are often challenging and limited for the maintenance of weight reduction, pharmacotherapy should be considered in a timely manner for obese men or overweight patients with weight-related comorbidities. Recent advances in anti-obesity drugs have enabled the potential of achieving clinically significant weight loss. Increasing evidence has shown that behavior-based interventions with one of these medications can result in greater weight loss than that elicited by usual care conditions. Data from most recent meta-analyses showed that the overall placebo-subtracted weight reduction (%) with the use of anti-obesity drugs for at least 12 months ranges from 2.9% to 6.8%; phentermine/topiramate (−6.8%) liraglutide (−5.4%), naltrexone/bupropion (−4.0%), lorcaserin (−3.1%), and orlistat (−2.9%). However, they have a high cost and may cause adverse outcomes depending on the individual. Very recently, on February 13, 2020, the US Food and Drug Administration requested withdrawal of lorcaserin from the market because a safety clinical trial showed an increased occurrence of cancer. Therefore the decision to initiate drug therapy in obese individuals should be made after the benefits and risks are considered. Thereafter, treatment should be tailored to specific patient subpopulations depending on their chronic conditions, comorbidities, and preferences. Herein, we provide an overview of the latest developments in weight loss medications, which may serve as one of the strategies for long-term obesity control.

    Keywords
    Liraglutide; Lorcaserin; Naltrexone/bupropion; Obesity; Orlistat; Phentermine/topiramate

    INTRODUCTION

    Recently, the “epidemic of obesity” has emerged as one of the major global health concerns. Between 1975 and 2016, the worldwide prevalence of obesity tripled and was primarily attributed to the intake of a high calorie diet and a sedentary lifestyle [1]. Although the prevalence of being overweight was similar between men (39%) and women (40%) in 2016 according to the World Health Organization, recent studies have reported more rapid increases in obesity-related indicators in men than in women [2, 3]. This sex disparity can be explained by genetic, sociocultural, socioeconomic, and behavioral factors [4]. After starting a career, men might succumb to obesogenic environmental changes—frequent dining outside the home, drinking, and stress, which ultimately lead to high calorie intake [3]. Men also tend to have lower body image dissatisfaction than women. Resultantly, they tend to be less interested in the weight gained over time than women [5].

    Excess fat distribution displays different patterns according to gender; it is concentrated in the centrally located visceral areas in men and subcutaneous areas in premenopausal women [6]. This difference may explain the greater negative impact of obesity on the cardiovascular health of men than on that of premenopausal women. Unlike subcutaneous fat, visceral fat is related to the worsening of insulin resistance and lipid and fluid metabolism [4]. Additionally, obesity in men predominantly reduces total testosterone due to the insulin resistance-associated decrease in sex hormonebinding globulin. Severe obesity is also related to reductions in free testosterone levels via suppression of the hypothalamic–pituitary–thyroid axis, whereas low testosterone alone results in increases in adiposity, thereby establishing a self-perpetuating cycle of metabolic impairment [7, 8]. Previously, obese men were found to have a greater risk of erectile dysfunction (ED). In fact, obesity can cause vasculogenic ED, which has common features, including obesity-related metabolic alterations [9].

    Timely and appropriate treatment to reduce excessive body fat is required in men with a body mass index (BMI) ≥30 kg/m2 (25 kg/m2 for some ethnic groups), ≥27 kg/m2 (23 kg/m2 for some ethnic groups) and obesity-related comorbidities or abdominal obesity (waist circumference [WC] ≥102 cm [90 cm for some ethnic groups]) [10, 11]. Although intensive lifestyle modification, including calorie restriction and engaging in physical activities, is the first approach to ameliorate obesity, sustaining these efforts over a long period can be challenging and often prove insufficient [12]. Currently, most guidelines recommend pharmacotherapy as a second-line treatment for weight management after lifestyle modification [13, 14]. In fact, numerous medications have been developed for the long-term management of obesity, with different mechanisms targeting various factors and diverse pathways that might cause a positive energy balance [15]. During the last decades, some anti-obesity drugs have been used to treat morbid obesity; however, most of these have been removed from the market owing to serious long-term side effects, particularly cardiovascular-related issues [16]. Since then, efforts to develop anti-obesity drugs have been made focusing on not only weight loss efficacy but also cardiovascular safety and lowered risk of cardiovascular disease (CVD). In recent years, the US Food and Drug Administration (FDA) has approved newer pharmacological options following more cautious studies elucidate their safety and efficacy [17]. As these anti-obesity drugs are approved for long-term management, they provide a better appreciation of the complex, chronic, and relapsing nature of obesity [18]. Importantly, the availability of different medications offers healthcare providers more options for deriving better patient-tailored treatment plans. In this review, we aimed to provide an overview of the latest developments in weight loss medications, which may serve as one of the strategies for long-term obesity control (Table 1).

    Table 1
    A summary of anti-obesity drugs for long-term use

    ANTI-OBESITY DRUGS FOR LONG-TERM USE

    1. Orlistat

    Orlistat (Xenical®) was first approved by the FDA in 1999. Today, it remains the longest licensed antiobesity drug for long-term use and is available over the counter (Alli®). As a non-central nervous system agent, orlistat 120 mg is prescribed for adults and adolescents ≥12 years of age [19].

    1) Mechanism of action

    Unlike other anti-obesity drugs on the market, orlistat does not exert its effect by affecting appetite; instead, it reduces calorie absorption. The main mechanism of orlistat is the inhibition of gastric and pancreatic lipases, which leads to a ~30% decrease in the absorption of intestinal triglycerides and thus calories [20]. Orlistat is expected to have little effect on weight loss with non-fatty food consumption.

    2) Side effects

    Common side effects of orlistat include fatty/oily stools, increased defecation, fecal urgency, and flatus with discharge. However, by co-prescribing a fiber-containing supplement—psyllium, its gastrointestinal side effects can be reduced.

    3) Clinical efficacy

    In the XENDOS (XENDOS (XENical in the prevention of Diabetes in Obese Subjects) trial, the largest randomized controlled trial (RCT) that evaluated the effect of orlistat in 3,305 patients, orlistat was found to cause a total body weight loss of 2.4% after 4 years. More importantly, it significantly lowered the risk of type 2 diabetes mellitus (T2DM), compared to placebo (6.2% vs. 9.0%), over 4 years [21]. Orlistat also improved blood pressure (BP), insulin sensitivity, and lipid profiles owing to its primary action of decreasing intestinal fat absorption. However, in this study, 91% of participants administered orlistat experienced at least one gastrointestinal event and 8% withdrew from the study due to adverse events. Further, there are concerns regarding the potential risk of colorectal cancer due to the presence of excess fat in the colon. In animal models, orlistat was associated with clusters of apoptosis-resistant, neoplastic, premalignant colonic lesions [22]. However, a large retrospective matched cohort study (n=33,625 on orlistat; 160,374 on placebo) showed no evidence of an increased risk of colorectal cancer after the initiation of orlistat [23]. Meanwhile, a significant decrease in the absorption of vitamins A, D, E, and K was observed in participants administered orlistat [21]. To prevent possible deficiencies in fat-soluble vitamins (such as vitamin D), a supplement can be recommended.

    2. Lorcaserin

    Lorcaserin (Belviq® and Belviq XR®) is a selective agonist of the 5-hydroxytryptamine (5-HT) 2C receptors and a Drug Enforcement Administration (DEA) schedule IV-controlled medication. In 2016, its extended released (XR) form (once daily [QD] 20 mg of lorcaserin) was approved by the FDA following twice-daily (BID) 10 mg of lorcaserin in 2012. However, on February 13, 2020, the FDA requested that the drug manufacturer voluntarily withdraw lorcaserin from the US market because it was determined that potential risk of cancer associated lorcaserin outweighs the benefits [24]. It was an update to the FDA Drug Safety Communication: Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin) issued on January 14, 2020 [25]. This withdrawal came after the FDA's reviewing data from the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients – Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) clinical trial to evaluate the risk of CVD problems [26]. It was a randomized, double-blind, placebo-controlled, multicenter, parallel group trial conducted between January 2014 and June 2018 in the US, Canada, Mexico, the Bahamas, Europe, South America, Australia, and New Zealand. The study population consisted of 12,000 men and women who were overweight or obese. Patients were required to have either established CVD, or to be at least 50 years old for men or 55 years for women with T2DM plus at least one additional cardiovascular risk factor. Eligible patients were assigned randomly to either lorcaserin 10 mg BID or placebo. Approximately 96% of patients completed the study, and 62% who completed remained on treatment at the end of study. The median follow-up time was 3 years and 3 months. The primary safety analysis showed no meaningful difference between lorcaserin and placebo in the risk of major adverse cardiovascular events, demonstrating noninferiority. However, it was found that more patients taking lorcaserin (n=462; 7.7%) were diagnosed with cancer compared to those taking a placebo, which is an inactive treatment (n=423; 7.1%). A range of cancer types was reported, with several different types of cancers occurring more frequently in the lorcaserin group, including pancreatic, colorectal, and lung. There was no apparent difference in the incidence of cancer over the initial months of treatment, but the imbalance increased with longer duration on lorcaserin.

    On the other hand, lorcaserin has failed to gain approval from the European Medical Agency (EMA) due to preclinical data that revealed the potential of breast cancer development and concerns regarding psychiatric issues—the aggravation of depression, suicidal ideation, and psychosis and valvulopathy. Moreover, phase III studies to determine the difference in adverse event incidence between groups were deemed underpowered [27].

    1) Mechanism of action

    Lorcaserin decreases food intake by increasing satiety through its serotonin anorectic effect by stimulating the proopiomelanocortin (POMC) receptors in the arcuate nucleus of the hypothalamus [28]. At least 14 serotonin receptor subtypes that modulate different physiological functions, ranging from hallucinations to muscle contraction, exist [29]. The side effects caused by non-specific serotonin agonists (i.e., fenfluramine and dexfenfluramine) are due to the stimulation of the peripheral serotonin 2B receptor. Fenfluramine is a predominant 5-HT2b receptor agonist that is believed to cause adverse CVD effects by stimulating mitotic activity and subsequent cell overgrowth within the valve leaflets [30]. Owing to its high selectivity for 5-HT2c receptor (15-fold and 100-fold selectivity over the 5-HT2A and 5-HT2B receptors, respectively), lorcaserin can suppress appetite and hunger without triggering pulmonary hypertension or valvular heart defects [31]. Many studies suggest that lorcaserin has multiple psychological effects—reducing craving and impulsivity and elevating satiety), which contribute to weight loss.

    2) Side effects

    The common side effects of lorcaserin include nausea, headache, dizziness, fatigue, dry mouth, cough, constipation, hypoglycemia, and back pain.

    3) Clinical efficacy

    Lorcaserin was evaluated in the BLOOM (Behavioral Modification and Lorcaserin for Obesity and Overweight Management) and BLOSSOM (Behavioral Modification and Lorcaserin Second Study for Obesity Management), randomized, double-blind, placebo-controlled phase III trials, which sought to investigate the efficacy and safety of different doses of lorcaserin. In the BLOOM study, 3,182 participants aged 18–65 with a BMI ranging from 30–45 kg/m2 received either 10 mg lorcaserin BID or placebo for 52 weeks [32]. At the end of the trial, participants in the lorcaserin group continued the intake of lorcaserin at the same dose or placebo for an additional 52 weeks. All patients were given diet and exercise counseling. At the conclusion of the trial, a weight loss greater than 10% was achieved in 22.6% of participants in the lorcaserin group vs. 7.7% in the placebo group. Of the participants administered lorcaserin for an additional 52 weeks, 67.9% of those who had an initial weight reduction >5% maintained this loss compared to the 50.3% patients re-randomized to receive placebo. In the BLOSSOM study, 4,008 patients between 18–65 years of age with a BMI from 30–45 kg/m2 received either 10 mg QD or 10 mg BID of lorcaserin or placebo. After 52 weeks, significantly more participants administered either 10 mg QD or 10 mg BID of lorcaserin lost >10% of body weight (22.6% and 17.4%, respectively), compared to 9.7% in the placebo group [33]. In a more recent RCT, 12,000 patients with a BMI >27 kg/m2 and confirmed CVD in men >50 or women >55 years of age were administered 10 mg BID lorcaserin vs. placebo. This study primarily assessed the cardiovascular safety and efficacy of this medication after 1 year. Based on the findings, 14.6% of subjects in the lorcaserin group had lost >10% weight compared to 4.8% of subjects in the placebo group who had a similar CVD risk at the 3.3-year median follow-up [34]. Lorcaserin resulted in a weight loss of ~3.3% from the baseline total body weight and improved fasting glucose, fasting insulin, and hemoglobin A1c (HbA1c) levels. In a smaller cohort of the BLOOM-DM (Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial, which comprised 603 overweight or obese patients with T2DM and HbA1c 7.0% to 10.0%, a mean reduction in HbA1c was found in the lorcaserin group compared to the placebo group (0.9% vs. 0.4%) [35]. Due to the concerns regarding the potential effect of lorcaserin on other types of 5-HT receptors, which could thus affect valvular competency, patients were monitored with serial echocardiograms during these phase III trials. A pooled risk of 1.15 (95% confidential interval=0.81–1.67) was found for the FDA-defined valvulopathy, suggesting that an unacceptable increase in the risk of valvulopathy was not present with the use of lorcaserin [36]. Although many long-term trials demonstrated beneficial effects of lorcaserin in T2DM and its substantial CVD safety profiles, weight loss efficacy of lorcaserin is only modest.

    3. Phentermine/topiramate

    Phentermine/topiramate ER (Qysmia®) was approved by the FDA in 2012 as the first combination agent for the long-term management of obesity. However, the EMA has not approved this medication due to its abuse potential, the lack of long-term data on the cardiovascular effects of phentermine, and the cognitive side effects of topiramate—attention, language, and memory impairment [27]. As this drug combination contains phentermine, it is a controlled DEA schedule IV substance.

    1) Mechanism of action

    This drug combination mainly suppresses appetite through mechanisms that remain unclear. The central sympathetic action of phentermine, a noradrenergic agonist, is to enhance the release of norepinephrine, dopamine, and serotonin [37]. Topiramate, a gamma-aminobutyric acid agonist, glutamate antagonist, and carbonic anhydrase inhibitor, was approved for the treatment of epilepsy and prophylaxis of migraines [38]. However, significant weight loss was observed among epileptic patients treated with topiramate, thereby leading to its evaluation in clinical studies for the treatment of obesity. Although the actions of topiramate on the central nervous system have not been completely understood, rodent studies have suggested that it acts as a neurostabilizer and may boost thermogenesis [39, 40].

    2) Dose escalation and side effects

    Phentermine/topiramate is prescribed for QD use. To prevent insomnia, its known side effect, it is recommended that this medication is taken in the morning. According to the package insert, the dose of phentermine/topiramate should be gradually escalated. After a starting dose of 3.75/23 mg QD is administered for 2 weeks, 7.5/46 mg is administered; this dose was best tolerated by the participants in the study. The dose should be administered for a minimum of 3 months before a further increase to the highest dose of 15/92 mg. Additionally, the dose is only increased if the patient fails to achieve a total body weight loss of 3% after 3 months. If the patient tolerates the medication poorly, a slow titration down or off (ideally over 3–5 days) is warranted to reduce the risk of seizure; this result was found in a study where patients with a history of seizures abruptly discontinued topiramate intake [18]. Common side effects of phentermine/topiramate ER include insomnia, paresthesia, dizziness, dry mouth, dysgeusia, and constipation [38]. A fetal safety issue also exists with this medication: it increases the risk of oral clefts. Thus, advice on contraceptive planning is imperative before this medication is prescribed to women of child-bearing age.

    3) Clinical efficacy

    Regarding weight loss efficacy, adequate assessments of phentermine/topiramate ER have been conducted via long-term studies. EQUIP and CONQUER were each one-year, randomized, double-blind, placebo-controlled studies comprising 1,267 and 2,487 participants, respectively [41, 42]. The EQUIP trial included non-diabetic patients with a BMI ≥35 kg/m2 whereas the CONQUER study included patients with a BMI ranging from 27–45 kg/m2 and more than two obesity-related comorbid conditions. The study findings enabled the approval of phentermine/topiramate ER by the FDA. In the EQUIP study, the mean weight loss at 1 year for participants in the phentermine/topiramate ER 15/92 mg group was 10.9%, compared to 1.6% in the placebo group. Similarly, in the CONQUER trial, participants administered the same dose of phentermine/topiramate ER for 1 year achieved a 9.8% reduction in weight from baseline, compared to 1.2% in the placebo group. In the CONQUER trial, patients administered phentermine/topiramate ER 7.5/46 mg for 1 year had a total body weight loss of 7.8%. Notably, both studies demonstrated an improvement in the cardiovascular risk factors. The SEQUEL study, a 2-year extension trial, was performed to assess the sustained weight loss of participants after completion of the CONQUER trial [43]. The study findings reinforced previous findings that phentermine/topiramate ER intake can result in meaningful weight loss and significant improvements in BP, lipid profiles, fasting glucose, fasting insulin, and WC.

    4. Naltrexone/bupropion

    Naltrexone/bupropion (Contrave®) is a drug combination for the long-term management of weight loss. In 2014, this combination was approved the FDA (Mysimba® approved by the EMA). Each component of this medication has been used in other medical conditions since the 1980s [18]. As there is no potential of abuse with this medication, it is not a controlled substance.

    1) Mechanism of action

    As an antidepressant, bupropion is used as a smoking cessation aide. Its anorectic mechanism of action involves the inhibition of dopamine and norepinephrine reuptake. Naltrexone was approved for the treatment of opioid and alcohol addiction and antagonizes an opioid-dependent feedback loop that limits the effects of bupropion on the POMC neurons; hence, this drug combination works synergistically [44].

    2) Dose escalation and side effects

    A slow dose escalation of naltrexone/bupropion is recommended to minimize the side effect of nausea, with a starting dose of 8/90 mg (a single combination tablet) QD for 1 week (at week 2; 1 tablet BID in the morning and evening, at week 3; 2 tablets in the morning and 1 tablet in the evening, at week two tablets BID (the maximum dose). Typical side effects include headache, dizziness, dry mouth, and gastrointestinal discomfort (i.e., nausea, vomiting, constipation, or diarrhea). Although naltrexone/bupropion results in significant weight reduction and long-term evidence to support its efficacy exists [18], its side effects of elevation of BP and heart rate make it challenging to prescribe to patients with significant CVD.

    3) Clinical efficacy

    Naltrexone/bupropion was assessed in four phase III multicenter, long-term, double-blind placebo-controlled trials. The COR (Contrave Obesity Research)-I (n=1,742), COR-II (n=1,496), and COR-BMOD (Behavior MODification) (n=793) trials included patients with a BMI ≥27 kg/m2, at least one weight-related comorbid condition (i.e., hypertension [HTN]), and COR-DM (Diabetes Mellitus) [45, 46, 47, 48]. The percent weight loss observed in COR-I, COR-II, and COR-BMOD in patients administered naltrexone/bupropion 32/360 mg for 56 weeks compared to placebo was 6.1% vs. 1.3%, 6.4% vs. 1.2%, and 9.3% vs. 5.1%, respectively [49]. The final study, the COR-DM trial, evaluated weight loss in 505 patients with T2DM who were either overweight or obese [48]. Here, patients administered naltrexone/bupropion 32/360 mg for 56 weeks vs. placebo lost 5.0% vs. 1.8%. Moreover, their HbA1c was reduced relative to the baseline value (0.6% vs. 0.1%) [50]. These trials revealed improvements in high-density lipoprotein cholesterol and triglycerides in naltrexone/bupropion-treated patients. However, improvements in WC, fasting insulin, and insulin resistance index (homeostasis model assessment of insulin resistance, HOMA-IR) were only identified in participants in the COR-I, COR-II, and COR-BMOD studies [51].

    5. Liraglutide

    Liraglutide (Saxenda®) is an injectable glucagon-like peptide 1 (GLP-1) derivative that was approved by the FDA in 2014 for weight management (dose, 3.0 mg subcutaneous [SC] daily). This approval followed that of a lower dose (1.8 mg daily [Victoza®]) in 2010 for T2DM management [52].

    1) Mechanism of action

    After meals, GLP-1 is secreted from the distal ileum, proximal colon, and the vagal nucleus of the solitary tract and exhibits multiple effects as an incretin hormone [53]. GLP-1 mainly regulates blood glucose by enhancing insulin secretion from the pancreatic beta-cells and inhibits glucagon secretion in a glucose-dependent manner. GLP-1 also induces postprandial satiety and fullness, slows gastric emptying, and decreases appetite and food consumption by acting on the hypothalamus, limbic/reward system, and cortex [54]. Unlike human GLP-1, liraglutide is more stable in plasma and binds strongly to plasma proteins, thereby enabling a much longer half-life (13 hours) than the human endogenous GLP-1 (a few minutes) [55].

    2) Dose escalation and side effects

    The optimal dose of liraglutide for weight loss is 3 mg daily; however, to prevent the side effects of nausea and vomiting, treatment should be initiated with 0.6 mg QD and gradually escalated each week by 0.6 mg up to 3 mg [38]. Previously, a meta-analysis revealed that among all FDA-approved anti-obesity medications, liraglutide had the highest discontinuation rate due to its side effects (13% of patients) [56]. The most frequent placebo-subtracted side effects were nausea (25.0%), vomiting (12.2%), diarrhea (11.6%), constipation (11.0%), and dyspepsia (6.4%), which were tolerated by most patients over time [57, 58, 59].

    3) Clinical efficacy

    Liraglutide was approved base on the results of three main RCTs; The SCALE Obesity and Prediabetes, the SCALE Diabetes and the SCALE Maintenance [58, 60, 61]. In the SCALE Obesity and Prediabetes, obese participants (n=2,487), including 61.2% of the prediabetic cohort, received liraglutide 3 mg QD or placebo. After 56 weeks, a weight loss of 8.0% was achieved in the liraglutide group (vs. 2.6% of placebo) and 63.2% and 33.1% of the participants in the liraglutide group achieved ≥5% and ≥10% weight reduction, respectively [58] (vs. 27.1% and 10.6% in the placebo group, respectively). Moreover, cardiovascular indicators, including BP and lipid profiles, were better improved in the treatment group. Particularly, HbA1c (−0.30%±0.28%) and fasting glucose levels (−7.1±0.8 mg/dL) were significantly reduced in subjects administered liraglutide 3.0 mg compared to placebo. The SCALE Diabetes assigned overweight or obese patients with T2DM (n=846) to receive liraglutide 3 mg QD or 1.8 mg QD or placebo for 56 weeks and reported a decrease in the weight of the patients (6.0%, 4.7%, and 2.0%, respectively) [58]. Early achievement of weight loss ≥4% with liraglutide 3 mg (at 16 weeks) was associated with greater weight reduction at the study's termination [62]. Compared to the 1.8 mg SC daily group, the liraglutide 3.0 mg SC daily group had a greater improvement in the T2DM measures, including HbA1c, fasting plasma glucose, HOMA-IR, and number of hypoglycemic agents. The SCALE Maintenance aimed to evaluate weight maintenance in non-diabetic participants who underwent a ≥4-week run-in with a low-calorie diet. Subjects who lost ≥5% of their body weight (n=422) were randomized to receive liraglutide 3.0 mg SC daily or placebo for 56 weeks. The liraglutide 3.0 mg SC daily group achieved an additional weight loss of 6.2% (0.2%, placebo) [61]. One of the main benefits of liraglutide, besides weight loss, is its favorable effects on CVD outcomes in obese patients with T2DM.

    Despite initial considerations of the risk of acute pancreatitis, long-term trials suggest that the risk of this disease does not significantly increase with liraglutide [63, 64]. Particularly, biomarkers of acute pancreatitis—amylase and mainly lipase—increase in a non-dose dependent manner during treatment with GLP-1 receptor analogs. However, their increase was not accompanied by symptoms; moreover, when monitored, acute pancreatitis could not be predicted [65]. Based on rodent studies that demonstrated the proliferative effect of liraglutide on thyroid C-cells, contraindications for liraglutide include patients with (or a family history of) medullary thyroid carcinoma or type 2 multiple endocrine neoplasia [27]. In rodents administered incretin-based medications, pancreatic, intestinal, and breast neoplasms were found to develop more frequently; however, these results were not found in human studies [66, 67, 68]. A phase IIIb RCT reported no difference in calcitonin levels and medullary thyroid carcinoma rates between liraglutide (≤1.8 mg) and placebo during a follow-up of 3.5–5 years [69]. Additionally, the total risk of malignant and benign neoplasms, including pancreatic cancer, was not found to increase in the liraglutide vs. placebo group [63, 64, 70]. However, these results should be interpreted cautiously and an intensive post-marketing surveillance of liraglutide should be performed as the studies were not designed to assess cancer risk and the incidence of medullary thyroid carcinoma was too low for detection in the trials. As no concern regarding neuropsychiatric safety was reported, this medication can serve as a good option for obese patients with mental disorders [71] if they can afford this costly medication (liraglutide 3.0 mg) and agree to a daily injection.

    COMBINATION OF ANTI-OBESITY DRUGS IN CLINICAL DEVELOPMENT

    As obesity occurs via multifactorial pathways, a single drug might exhibit limited efficacy. Thus, a high dose might be required, which often causes unacceptable side effects. Combination therapy comprising multiple anti-obesity drugs with complementary modes of action is warranted to broaden the target energy regulatory systems via actions on distinct mechanisms, which could maximize the effect on weight management while maintaining safety and tolerability [72]. To date, however, there has been no approved combination agent for obesity management, besides phentermine/topiramate and naltrexone/bupropion. Other co-administered medications have been investigated to elucidate their long-term efficacy and adverse events [15, 16]. Most combinations primarily focus on both controlling hunger/appetite/satiety and inhibiting peripheral calorie absorption (i.e., phentermine/sodium glucose co-transporter 2 [SGLT-2] inhibitor, a GLP-1 agonist/other gut hormones, or an SGLT-2 inhibitor). SGLT-2 inhibitors, such as dapagliflozin, empagliflozin, and canagliflozin, block glucose reabsorption from the renal tubules and result in glycosuria. Therefore, they are primarily used by diabetic patients for blood sugar control [73]. Interestingly, these drugs are effective, to some extent, in individuals without diabetes [74]. Theoretically, the amount of glucose loss in urine is approximately 75 g/d (300 kcal energy deficit). Resultantly, 7–8 kg of weight loss owing to these medications can be expected in patients with diabetes over 6–12 months. However, in previous clinical studies with diabetic patients, only 2–3 kg weight loss was achieved with such agents; this was attributed to compensatory hyperphagia/increased appetite [75]. Thus, combining an appetite suppressor, such as phentermine, with a SGLT-2 inhibitor can serve as a good option for weight management. In a recent clinical trial that examined canagliflozin in combination with phentermine, additional weight loss was achieved (6.9%, canagliflozin 300 mg+phentermine 15 mg vs. 1.3%, canagliflozin 300 mg vs. 3.5%, phentermine 15 mg) [76]. Similarly, SGLT-2 inhibitors combined with a GLP-1 agonist caused a greater weight reduction than individual administration of each agent [77].

    INITIATING AND TERMINATING PHARMACOTHERAPY FOR OBESITY

    Despite the marked availability, anti-obesity drugs are reported to be underused by healthcare providers [3, 78]. Only 2% of obese adults who are eligible for obesity pharmacotherapy receive prescriptions for these agents from their doctor [79]. As a highly stigmatized disease, there remains a misconception that obesity is mainly due to a lack of willpower and representative of laziness; thus, these patients are considered undeserving of proper treatment with medications or surgery [80]. The high cost of these medications also prevents adequate prescription for long periods. Weight loss is extremely challenging to achieve and sustain, and long-term management of obesity often requires adjunctive pharmacological interventions. Today, practitioners have access to several FDA-approved options. Moreover, as there is growing evidence that these drugs can delay the onset of obesity-related complications and improve metabolic and cardiovascular parameters, they should be considered in a timely manner.

    The decision to initiate drug therapy in an obese individual should be made after the risks and benefits are considered. Importantly, health providers should determine the risk-benefit profile of a given anti-obesity drug on a patient-by-patient basis. Further, the treatment goals should be clear. Patient preferences based on tolerability markedly affect adherence and can cause poor adherence or discontinuation, thereby negating the treatment effects [13, 14]. At every visit, physicians should discuss the adverse events that accompany a given drug and evaluate the drug's effect on weight loss. The goal of treatment with anti-obesity drugs in obese individuals should be long-term maintenance of weight reduction and improvement in overall health.

    In most clinical trials that evaluated pharmacologic interventions for more than 12 months, a weight loss of 4% to 8% was typical [56]; however, this is rather disappointing considering the high prices of these drugs. Therefore, upon initiation of an anti-obesity medication, health providers must communicate several important messages to their patients. First, not every drug will produce effective results in patients and individual responses will vary widely. Second, when the maximal therapeutic effect of a drug is achieved, a plateau will be reached. Lastly, when drug therapy is discontinued, weight regain is normally expected.

    Treatment response to most of these drugs should be evaluated at around 12 weeks using the maintenance dose. A trial period of 3 to 4 months is essential for predicting whether a patient might achieve a clinically significant weight loss at 1 year (classified as responders or non-responders); this is supported by data that early weight loss with any medical intervention is a good indicator of long-term outcomes [62, 81, 82, 83]. Recently approved anti-obesity drugs have “stopping rules” that are suggested by the FDA and EMA to help clinicians identify patients that might achieve a weight reduction >5% within 1 year. Stopping rules can avoid unnecessary exposure and enhance the risk–benefit ratio [27]. If <5% weight loss is achieved after 12 weeks of treatment with a full dose (<4% weight loss at 16 weeks for liraglutide), the medication should be discontinued and other drugs should be considered. However, it can be difficult for practitioners to determine whether to continue the use of a given anti-obesity drug at the twelfth week, if the full dose has not been administered. Additionally, stopping rules are based on the results of the trials that conducted combined interventions involving an anti-obesity drug and intensive lifestyle modifications not medication only. Thus, the decision regarding the further continuation of a given medication should be made according to its effectiveness at reducing weight when diet, exercise, and behavioral modifications are adopted. Without a low-calorie diet and an increase in physical activity, the application of a medication alone could lead to failure to achieve weight reduction of 5% even after 12 weeks of treatment.

    CONCLUSION

    As the morbidity and mortality of obesity have significantly increased, most current guidelines recommend pharmacotherapy as the second line of treatment for this disorder following lifestyle modifications. Pharmacological treatment should be considered as part of a comprehensive strategy for the treatment of patients with a BMI ≥30 or ≥27 kg/m2 and an obesity-related comorbidity—HTN, T2DM, dyslipidemia, and sleep apnea. Additionally, the efficacy of medical treatment should be evaluated after the first 3 months of drug use. Substantial research has been dedicated to the development of a newer generation of anti-obesity drugs. In recent years, many novel agents have undergone phase III clinical trials. Compared to placebo, these drugs cause a significant weight reduction, including meaningful improvements in cardiometabolic profiles, while demonstrating good tolerability and safety in patients with obesity. Data from most recent meta-analyses showed that the overall placebo-subtracted weight reduction (%) with the use of anti-obesity drugs for at least 12 months ranges from 2.9% to 6.8%; phentermine/topiramate (3 trials, −6.8%) liraglutide (4 trials, −5.4%), naltrexone/bupropion (5 trials; −4.0%), lorcaserin (4 trials; −3.1%), and orlistat (17 trials, −2.9%) (Table 2) [56, 84, 85, 86, 87, 88].

    Table 2
    Data from meta-analyses of the anti-obesity drugs approved for long-term use for weight loss

    Most prior trials conducted on these medications also performed an intensive consultation on diet and exercise in not only the placebo but also the treatment groups. Thus, these medications were proposed for use as pharmacotherapy in conjunction with healthy eating, physical activity, and behavior modification. Further, prior findings demonstrated that anti-obesity drugs cannot be used as a panacea for the treatment of obesity; instead, they should be used to facilitate weight control.

    Notes

    Conflict of Interest:The authors have nothing to disclose.

    Author Contribution:

    • Conceptualization: SYL.

    • Investigation: SYL, YJT.

    • Writing — original draft: YJT.

    • Writing — review & editing: SYL, YJT.

    References

      1. World Health Organization. Obesity and overweight. Fact sheet [Internet]. Geneva: World Health Organization; c2018 [cited 2020 Jan 12].
        Available from: http://www.who.int/mediacentre/factsheets/fs311/en/.
      1. Chen Y, Peng Q, Yang Y, Zheng S, Wang Y, Lu W. The prevalence and increasing trends of overweight, general obesity, and abdominal obesity among Chinese adults: a repeated cross-sectional study. BMC Public Health 2019;19:1293
      1. Park YW, Choi KB, Kim SK, Lee DG, Lee JH. Obesity in Korean men: results from the fourth through sixth Korean National Health and Nutrition Examination Surveys (2007~2014). World J Mens Health 2016;34:129–136.
      1. Palmer BF, Clegg DJ. The sexual dimorphism of obesity. Mol Cell Endocrinol 2015;402:113–119.
      1. Hwang JH, Ryu DH, Park SW. Interaction effect between weight perception and comorbidities on weight control behavior in overweight and obese adults: Is there a sex difference? J Korean Med Sci 2015;30:1017–1024.
      1. White UA, Tchoukalova YD. Sex dimorphism and depot differences in adipose tissue function. Biochim Biophys Acta 2014;1842:377–392.
      1. Fui MN, Dupuis P, Grossmann M. Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J Androl 2014;16:223–231.
      1. Masterson JM, Soodana-Prakash N, Patel AS, Kargi AY, Ramasamy R. Elevated body mass index is associated with secondary hypogonadism among men presenting to a tertiary academic medical center. World J Mens Health 2019;37:93–98.
      1. Moon KH, Park SY, Kim YW. Obesity and erectile dysfunction: from bench to clinical implication. World J Mens Health 2019;37:138–147.
      1. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. National Institutes of Health. Obes Res 1998;6 Suppl 2:51S–209S.
      1. Lee SY, Park HS, Kim DJ, Han JH, Kim SM, Cho GJ, et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. Diabetes Res Clin Pract 2007;75:72–80.
      1. Curioni CC, Lourenço PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond) 2005;29:1168–1174.
      1. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014;129:S102–S138.
      1. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 2016;22 Suppl 3:1–203.
      1. Bhat SP, Sharma A. Current drug targets in obesity pharmacotherapy - a review. Curr Drug Targets 2017;18:983–993.
      1. Coulter AA, Rebello CJ, Greenway FL. Centrally acting agents for obesity: past, present, and future. Drugs 2018;78:1113–1132.
      1. Daneschvar HL, Aronson MD, Smetana GW. FDA-approved anti-obesity drugs in the United States. Am J Med 2016;129:879.e1–879.e6.
      1. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100:342–362.
      1. Xenical (orlistat) patient information [Internet]. South San Francisco (CA): Genentech USA, Inc.; c2016 [cited 2020 Jan 1].
        Available from: https://www.aace.com/files/obesity/tool-kit/xenical_patient_info.pdf.
      1. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74–86.
      1. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–161.
      1. Garcia SB, Barros LT, Turatti A, Martinello F, Modiano P, Ribeiro-Silva A, et al. The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett 2006;240:221–224.
      1. Hong JL, Meier CR, Sandler RS, Jick SS, Stürmer T. Risk of colorectal cancer after initiation of orlistat: matched cohort study. BMJ 2013;347:f5039
      1. The US Food and Drug Administration. 2-13-2020 FDA drug safety communication [Internet]. Silver Spring (MD): The US Food and Drug Administration; c2020 [cited 2020 Feb 16].
        Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market.
      1. The US Food and Drug Administration. 01-14-2020 FDA drug safety communication [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c2020 [cited 2020 Jan 16].
        Available from: https://www.fda.gov/drugs/drug-safety-and-availability/safety-clinical-trial-shows-possible-increased-risk-cancer-weight-loss-medicine-belviq-belviq-xr.
      1. Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, et al. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet 2018;392:2269–2279.
      1. Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med 2018;130:173–182.
      1. Gustafson A, King C, Rey JA. Lorcaserin (Belviq): a selective serotonin 5-HT2C agonist in the treatment of obesity. P T 2013;38:525–534.
      1. Roth BL, Willins DL, Kristiansen K, Kroeze WK. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther 1998;79:231–257.
      1. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836–2841.
      1. Meltzer HY, Roth BL. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest 2013;123:4986–4991.
      1. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245–256.
      1. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011;96:3067–3077.
      1. Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018;379:1107–1117.
      1. O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426–1436.
      1. Weissman NJ, Sanchez M, Koch GG, Smith SR, Shanahan WR, Anderson CM. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging 2013;6:560–567.
      1. Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther 2009;16:354–364.
      1. Velazquez A, Apovian CM. Updates on obesity pharmacotherapy. Ann N Y Acad Sci 2018;1411:106–119.
      1. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res 2000;8:656–663.
      1. Richard D, Picard F, Lemieux C, Lalonde J, Samson P, Deshaies Y. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord 2002;26:344–353.
      1. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330–342.
      1. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341–1352.
      1. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297–308.
      1. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009;17:30–39.
      1. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595–605.
      1. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013;21:935–943.
      1. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19:110–120.
      1. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013;36:4022–4029.
      1. Fujioka K, Braverman-Panza J. Answers to clinical questions in the primary care management of people with obesity: pharmacologic management. J Fam Pract 2016;65:S16–S23.
      1. Jeon WS, Park CY. Antiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term management. Endocrinol Metab (Seoul) 2014;29:410–417.
      1. Apovian CM, Istfan NW. Obesity: guidelines, best practices, new research. Endocrinol Metab Clin North Am 2016;45:xvii–xviii.
      1. Upadhyay J, Polyzos SA, Perakakis N, Thakkar B, Paschou SA, Katsiki N, et al. Pharmacotherapy of type 2 diabetes: an update. Metabolism 2018;78:13–42.
      1. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014;38:784–793.
      1. Ten Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Drent ML, Diamant M, et al. Liraglutide reduces CNS activation in response to visual food cues only after short-term treatment in patients with type 2 diabetes. Diabetes Care 2016;39:214–221.
      1. Farr OM, Tsoukas MA, Triantafyllou G, Dincer F, Filippaios A, Ko BJ, et al. Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: a randomized, placebo-controlled, crossover study. Metabolism 2016;65:945–953.
      1. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:2424–2434.
      1. Lean ME, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rössner S, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond) 2014;38:689–697.
      1. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11–22.
      1. Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia 2016;59:954–965.
      1. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 2015;314:687–699.
      1. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013;37:1443–1451.
      1. Fujioka K, O'Neil PM, Davies M, Greenway F, C W, Claudius B, et al. Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity (Silver Spring) 2016;24:2278–2288.
      1. Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab 2017;19:1233–1241.
      1. Bahtiyar G, Pujals-Kury J, Sacerdote A. Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes. Curr Diab Rep 2018;18:92
      1. Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program. Diabetes Care 2017;40:839–848.
      1. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595–2604.
      1. Koehler JA, Baggio LL, Yusta B, Longuet C, Rowland KJ, Cao X, et al. GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab 2015;21:379–391.
      1. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150–156.
      1. Hegedüs L, Sherman SI, Tuttle RM, von Scholten BJ, Rasmussen S, Karsbøl JD, et al. No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for up to 5 years in the LEADER trial. Diabetes Care 2018;41:620–622.
      1. Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB. LEADER Publication Committee on behalf of the LEADER Trial Investigators. Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER randomized trial. Diabetes Care 2018;41:1663–1671.
      1. O'Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, et al. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab 2017;19:1529–1536.
      1. Wilding JP. Combination therapy for obesity. J Psychopharmacol 2017;31:1503–1508.
      1. Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia 2018;61:2118–2125.
      1. Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014;22:1042–1049.
      1. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499–508.
      1. Hollander P, Bays HE, Rosenstock J, Frustaci ME, Fung A, Vercruysse F, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care 2017;40:632–639.
      1. Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2016;4:1004–1016.
      1. Thomas CE, Mauer EA, Shukla AP, Rathi S, Aronne LJ. Low adoption of weight loss medications: a comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity (Silver Spring) 2016;24:1955–1961.
      1. Xia Y, Kelton CM, Guo JJ, Bian B, Heaton PC. Treatment of obesity: pharmacotherapy trends in the United States from 1999 to 2010. Obesity (Silver Spring) 2015;23:1721–1728.
      1. Colbert JA, Jangi S. Training physicians to manage obesity--back to the drawing board. N Engl J Med 2013;369:1389–1391.
      1. Handjieva-Darlenska T, Handjiev S, Larsen TM, van Baak MA, Jebb S, Papadaki A, et al. Initial weight loss on an 800-kcal diet as a predictor of weight loss success after 8 weeks: the Diogenes study. Eur J Clin Nutr 2010;64:994–999.
      1. Rissanen A, Lean M, Rössner S, Segal KR, Sjöström L. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord 2003;27:103–109.
      1. Fujioka K, Plodkowski R, O'Neil PM, Gilder K, Walsh B, Greenway FL. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Int J Obes (Lond) 2016;40:1369–1375.
      1. Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol 2020;13:53–64.
      1. Kuo HH, Wang KT, Lee YH, Lin PL, Liu ME, Lin CY, et al. Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: a systematic review and meta-analysis. J Clin Pharm Ther 2020;45:35–44.
      1. Singh AK, Singh R. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol. 2020 [doi: 10.1080/17512433.2020.1703109]
        [Epub].
      1. O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018;392:637–649.
      1. Dong Z, Xu L, Liu H, Lv Y, Zheng Q, Li L. Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines. Obes Rev 2017;18:1377–1385.
    Cited by
    Crossref 71
    Google Scholar 
    PubMed Central 35
    Web of Science 60
    MeSH Terms
    Anti-Obesity Agents*
    Cardiovascular Diseases
    Drug Therapy
    Female
    Humans
    Life Style
    Liraglutide
    Male
    Obesity
    Orlistat
    Overweight
    Risk Assessment
    United States Food and Drug Administration
    Weight Loss
    Metrics
    Share
    Links to
    Tables
    slide
    slide

    1 / 2

    ORCID IDs
    PERMALINK